Developing a new cancer treatment targeting specific proteins
Preclinical Development of the Novel Inhibitor of Apoptosis Proteins S2/IAPinh for Cancer Therapy
This study is looking at a new treatment that could help make chemotherapy work better for people with ovarian and pancreatic cancer by blocking certain proteins that help cancer cells survive.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-11001442 on NIH RePORTER |
What this research studies
This research focuses on improving treatments for epithelial ovarian cancer and pancreatic ductal adenocarcinoma, two aggressive forms of cancer. It investigates a novel small molecule that inhibits specific proteins responsible for cancer cell survival, aiming to enhance the effectiveness of existing chemotherapy. By blocking these proteins, the treatment seeks to promote cancer cell death and overcome resistance to current therapies. The research involves preclinical testing in laboratory models to evaluate the potential of this new approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with epithelial ovarian cancer or pancreatic ductal adenocarcinoma who have not responded well to standard treatments.
Not a fit: Patients with other types of cancer or those who have not been diagnosed with epithelial ovarian cancer or pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that improve survival rates for patients with difficult-to-treat cancers.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, indicating that this approach could be a meaningful advancement in cancer therapy.
Where this research is happening
Charleston, United States
- Medical University of South Carolina — Charleston, United States (Active)
Researchers
- Principal investigator: Hawkins, William G — Medical University of South Carolina
- Study coordinator: Hawkins, William G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.